Bupivacaine Spinal

Bupivacaine Hydrochloride In Dextrose · BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL · Injection, Solution · Subarachnoid · Hospira, Inc.

NDC 00409-3613-01 · 10 AMPULE in 1 CARTON / 2 mL in 1 AMPULE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now — FDA lists the reason as “other”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$28.50

Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$1,110

862 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Hospira, Inc.United States
analysis · label · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA071810
TE code: AP
Approval date: Dec 11, 1987
Patents / exclusivity: None on file

Shortage history

In shortage now — Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)Feb 20, 2018
Other
month 103 — 5× the typical 20-month injectable shortage
In shortage now — Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)Feb 20, 2018
Demand increase for the drug
month 103 — 5× the typical 20-month injectable shortage
In shortage now — Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Bupivacaine Hydrochloride In Dextrose (Injection, Solution)

Labeler	Strength	First seen	Last seen
Hospira, Inc.	BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL	Jul 15, 2026	Sep 3, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bupivacaine Spinal — NDC 00409-3613-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00409361301.

Free to cite with attribution — see how the data is put together.